Results 1 to 10 of about 55,457 (267)

Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety

Biomedicines, 2023
Taxanes (paclitaxel and docetaxel) are one of the most useful classes of anticancer drugs. Taxanes are highly hydrophobic; therefore, these drugs must be dissolved in organic solvents (polysorbate or Cremophor EL), which contribute to their toxicities ...
Niranjan Awasthi, Saisantosh Ponna, Urs Von Holzen   +2 more
exaly   +5 more sources

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report [PDF]

Case Reports in Oncology, 2017
Thymic carcinomas are rare malignant tumors, located in the anterior mediastinum. For the treatment of these carcinomas, several chemotherapy regimens have been suggested, including carboplatin plus paclitaxel.
Kunihiko Funaishi, Masahiro Yamasaki, Naomi Saito, Wakako Daido, Sayaka Ishiyama, Naoko Deguchi, Masaya Taniwaki, Nobuyuki Ohashi   +7 more
doaj   +4 more sources

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel [PDF]

Case Reports in Oncology, 2023
We present a rare phenomenon of a soft tumor hanging on the woman’s left upper arm that underwent necrosis from the distal aspect during chemotherapy for pancreatic cancer. The benign tumor, pedunculated lipofibroma, originally had normal color for 10 years and then became necrotic when she was treated with gemcitabine and nab-paclitaxel.
Hiraku Kokubu, Takeshi Nakanishi, Takeshi Kato, Noriki Fujimoto   +3 more
core   +5 more sources

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer

Therapeutic Advances in Medical Oncology, 2023
Background: Most patients with small-cell lung cancer (SCLC) experience disease progression after first-line chemotherapy. Notably, nab-paclitaxel monotherapy has antitumor activity in relapsed SCLC.
Rui Wan, Yanrong Guo, Xuezhi Hao, Zhijie Wang, Jianchun Duan, Jie Wang   +5 more
doaj   +3 more sources

Paclitaxel drives TREM2+ macrophage expansion underlying its inferior therapeutic efficacy compared to Nab-paclitaxel [PDF]

Nature Communications
Paclitaxel and nab-paclitaxel differ in therapeutic efficacy and modulation of the tumor immune microenvironment, yet the molecular basis remains poorly defined.
Yuqi Xing, Ruiqi Zhong, Qianchen Li, Xinwei Duan, Moyang Xu, Miao Yu, Chenying Liu, Junming He, Yi Sun, Yunling Wang, Xiaojing Guo, Yunfei Xu, Hongnan Mo, Fei Ma, Hongquan Zhang, Jun Zhan   +15 more
doaj   +2 more sources

Influence of Consecutive Nab-Paclitaxel Chemotherapy Cycles on Gut Microbiota and Pharmacokinetic Behavior [PDF]

Technology in Cancer Research & Treatment
Introduction Nab-paclitaxel is a mainstay of treatment for a broad spectrum of cancers and is typically administered over multiple cycles. The anti-mitotic effects of nab-paclitaxel are well-established.
Xinyue Zhang MS, Weiwei Xie MS, Yuqian Zhang MS, Ye Yuan MS, Jingpu Xu MS, Jian Liu MS   +5 more
doaj   +2 more sources

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel: Two Case Reports

Case Reports in Oncology, 2020
A standard chemotherapy regimen for advanced thymic carcinoma has not yet been established. We treated 2 cases of thymic carcinoma with carboplatin plus nanoparticle albumin-bound (nab)-paclitaxel, and nab-paclitaxel maintenance therapy.
Tomoyuki Araya, Toshiyuki Kita, Hiroki Matsuoka, Tamami Sakai, Hideharu Kimura, Kazuo Kasahara   +5 more
doaj   +3 more sources

NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial [PDF]

Nature Communications
In this phase 2 study (NCT05047991), patients with unresectable metastatic pancreatic adenocarcinoma were randomized to receive NALIRIFOX (liposomal irinotecan, 5-FU, leucovorin, and oxaliplatin) or gemcitabine plus nab-paclitaxel.
Chuntao Gao, Yanqiao Zhang, Xiujuan Qu, Xingyun Chen, Jingdong Zhang, Heshui Wu, Meili Sun, Yong Zha, Junbin Wang, Yusheng Wang, Zhihua Li, Jinghua Gao, Rongbo Lin, Aimin Zang, Huiqing Zhang, Xianglin Yuan, Chengyou Du, Jun Zhao, Yongsheng Yang, Xuetao Shi, Wei Cheng, Bangmao Wang, Shikai Wu, Tiansuo Zhao, Jian Wang, Song Gao, Xiuchao Wang, Weidong Ma, Rui Liu, Yehui Shi, Yanping Liu, Yijiao Xie, Miao Niu, Fuchen Zhao, Jun Yu, Jihui Hao   +35 more
doaj   +2 more sources

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas

Frontiers in Oncology, 2022
Taxanes (paclitaxel and docetaxel) play an important role in the treatment of advanced sarcomas. Albumin-bound paclitaxel (nab-paclitaxel) is a new kind of taxane and has many advantages compared with paclitaxel and docetaxel. Nab-paclitaxel is currently
Zhichao Tian, Weitao Yao
doaj   +1 more source

Intravitreal Ranibizumab Had Limited Effect on Cystoid Macular Edema Due to Albumin-Bound Paclitaxel: A Case Report and Literature Review

Frontiers in Oncology, 2021
Angiographically silent cystoid macular edema (CME) is a rare complication from nab-paclitaxel. Here we report a 45-year-old woman with breast cancer who developed CME after several months of treatment with albumin-bound paclitaxel (nab-paclitaxel).
Suna Ye, Suna Ye, Qiqi Fang, Jinyu Yao, Jianqiang Xing, Shibo Tang, Shibo Tang, Jacey Hongjie Ma, Jacey Hongjie Ma   +8 more
doaj   +1 more source